Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
28
CRSP Quote, Financials, Valuation and Earnings
Last price:
$40.74
Seasonality move
:
16.92%
Day range:
$39.41 - $41.02
52-week range:
$39.41 - $91.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.79x
Volume:
3.1M
Avg. volume:
2M
1-year change:
-33.04%
Market cap:
$3.5B
Revenue:
$370M
EPS (TTM):
-$2.80
Analysts' Opinion
-
Consensus RatingCRISPR Therapeutics AG has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 11 Hold ratings, and 2 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $81.75, CRISPR Therapeutics AG has an estimated upside of 100.76% from its current price of $40.72.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $30.00 representing 26.33% downside risk from its current price of $40.72.
Fair Value
-
According to the consensus of 24 analysts, CRISPR Therapeutics AG has 100.76% upside to fair value with a price target of $81.75 per share.
CRSP vs. S&P 500
-
Over the past 5 trading days, CRISPR Therapeutics AG has underperformed the S&P 500 by -5.1% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
CRISPR Therapeutics AG does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
CRISPR Therapeutics AG has grown year-over-year revenues for 1 quarter straight. In the most recent quarter CRISPR Therapeutics AG reported revenues of --.
Earnings Growth
-
CRISPR Therapeutics AG has grown year-over-year earnings for 0 quarters straight. In the most recent quarter CRISPR Therapeutics AG reported earnings per share of -$1.01.
Enterprise value:
1.5B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-8.05x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$69.8M
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $12.8M | -- | -- | -- | -- | |
| Gross Profit | -$122.5M | $52.9M | $69.8M | -$23.4M | -$11.2M | |
| Operating Income | -$687.3M | -$423.7M | -$332.4M | -$132.4M | -$110.1M | |
| EBITDA | -$662.7M | -$402.9M | -$313.1M | -$127.5M | -$105.4M | |
| Diluted EPS | -$8.80 | -$4.47 | -$2.80 | -$1.41 | -$1.01 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.4B | $2.5B | $1.9B | $1.8B | $1.9B | |
| Total Assets | $1.5B | $2.8B | $2.4B | $2.1B | $2.3B | |
| Current Liabilities | $84.1M | $96.2M | $150.9M | $111.2M | $89.8M | |
| Total Liabilities | $141.7M | $308.8M | $399.4M | $359M | $316.5M | |
| Total Equity | $1.3B | $2.5B | $2B | $1.7B | $1.9B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$468.5M | -$277.6M | -$188.8M | -$39.9M | -$106.9M | |
| Cash From Investing | -$91.8M | $280.6M | -$467.8M | $121.3M | -$161.6M | |
| Cash From Financing | $42.4M | $26.2M | $354M | $1.6M | $9.6M | |
| Free Cash Flow | -$508.6M | -$295.1M | -$191.2M | -$43M | -$107.1M | |
CRSP
Sector
Market Cap
$3.5B
$44.6M
Price % of 52-Week High
44.7%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
-33.04%
-29.09%
Beta (5-Year)
1.621
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$43.50
200-day SMA
Sell
Level
$53.99
Bollinger Bands (100)
Sell
Level
45.2 - 50.74
Chaikin Money Flow
Sell
Level
-34.4M
20-day SMA
Sell
Level
$47.77
Relative Strength Index (RSI14)
Sell
Level
33.92
ADX Line
Sell
Level
13.78
Williams %R
Buy
Level
-91.3474
50-day SMA
Sell
Level
$48.31
MACD (12, 26)
Sell
Level
-2.05
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Sell
Level
-23.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (8.8472)
Buy
CA Score
(Annual)
Level (0.7129)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-0.3424)
Buy
Piotroski F Score
(Annual)
Level (5)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Stock Forecast FAQ
In the current month, CRSP has received 11 Buy ratings 11 Hold ratings, and 2 Sell ratings. The CRSP average analyst price target in the past 3 months is $81.75.
-
Where Will CRISPR Therapeutics AG Stock Be In 1 Year?
According to analysts, the consensus estimate is that CRISPR Therapeutics AG share price will rise to $81.75 per share over the next 12 months.
-
What Do Analysts Say About CRISPR Therapeutics AG?
Analysts are divided on their view about CRISPR Therapeutics AG share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that CRISPR Therapeutics AG is a Sell and believe this share price will drop from its current level to $30.00.
-
What Is CRISPR Therapeutics AG's Price Target?
The price target for CRISPR Therapeutics AG over the next 1-year time period is forecast to be $81.75 according to 24 Wall Street analysts, 11 of them rate the stock a Buy, 2 rate the stock a Sell, and 11 analysts rate the stock a Hold.
-
Is CRSP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for CRISPR Therapeutics AG is a Buy. 11 of 24 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CRSP?
You can purchase shares of CRISPR Therapeutics AG via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase CRISPR Therapeutics AG shares.
-
What Is The CRISPR Therapeutics AG Share Price Today?
CRISPR Therapeutics AG was last trading at $40.74 per share. This represents the most recent stock quote for CRISPR Therapeutics AG. Yesterday, CRISPR Therapeutics AG closed at $40.72 per share.
-
How To Buy CRISPR Therapeutics AG Stock Online?
In order to purchase CRISPR Therapeutics AG stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
